Innate Pharma Sa Class A · EURONEXT:IPH
Innate Pharma Sa Class A — Investor Presentation (May 2019)
34 slides from Innate Pharma Sa Class A's investor presentation, May 29, 2019
Slide 1: Corporate Presentation 2Q19
CORPORATE PRESENTATION 2Q19
Slide 2: Forward Looking Statement
FORWARD LOOKING STATEMENT This document has been prepared by Innate Pharma S.A. (the or implied, is made as to, and no reliance should be placed on, “Company”) solely for the purposes of a presentation to the fairness, accuracy, completeness or correctness of the investors concerning the Company. Th
Slide 3: Innate Pharma Overview
INNATE PHARMA Overview LONG-TERM VALUE CREATION INNOVATIVE PIPELINE Building Blocks • First/best-in-class IO assets Partnered to Long-term Sustainable • 3 clinical stage programs Value-Creation • Multiple shots on goal Proprietary VALIDATING FULLY-INTEGRATED STRONG FINANCIAL PARTNERSHIPS BIOTECH POS
Slide 4: Innate Pharma – Our Strategy
INNATE PHARMA – OUR STRATEGY Overview STRATEGIC PRIORITIES Science Commercial Finances Partnered • Boost the research • Become fully • Continue to engine to fuel the integrated strengthen Proprietary pipeline & deliver oncology-focused financial position clinical program biotech to invest in proprie
Slide 5: Innate Pharma – Our Focus
INNATE PHARMA – OUR FOCUS Overview SCIENTIFIC EXCELLENCE AROUND 3 KEY PILLARS Science Partnered NK/T cell checkpoints • Boost the research engine to fuel the Tumor-microenvironment Proprietary pipeline & deliver clinical program Tumor-antigens Financial 5
Slide 6: Innate Pharma Portfolio
INNATE PHARMA PORTFOLIO Overview BROAD & BALANCED IMMUNO-ONCOLOGY FRANCHISE Signal Programs (target) Indications Preclinical Dose-finding Pivotal Commercial detection Proprietary Portfolio Lumoxiti (CD22) Hairy Cell Leukemia Partnered Sézary Syndrome IPH4102 (KIR3DL2) MF/ PTCL IPH5401 (C5aR) NSCLC/H
Slide 7: Partnered Portfolio: Monalizumab
PARTNERED PORTFOLIO: MONALIZUMAB FIRST-IN-CLASS ANTI-NKG2A MAB CO-DEVELOPMENT AND COMMERCIALIZATION AGREEMENT WITH ASTRAZENECA 7
Slide 8: Monalizumab – First-in-class anti-NKG2A mAb
MONALIZUMAB – FIRST-IN-CLASS ANTI-NKG2A MAB Overview PROMOTES ANTI-TUMOR IMMUNITY BY UNLEASHING BOTH T & NK CELLS • First-in-class checkpoint inhibitor targeting NKG2A receptors expressed on subsets of Partnered CD8 T cells & NK cells • Combined blocking of the NKG2A and the PD-1 axis promotes anti-
Slide 9: Monalizumab – Key Results with Cetuximab Combination
MONALIZUMAB – KEY RESULTS WITH CETUXIMAB COMBINATION Overview EARLY, DEEP AND DURABLE RESPONSES IN PATIENTS WITH R/M SCCHN ORR in All patients & according to prior IO Best change of tumor size from baseline Partnered Cut-off All patients IO-naïve IO-pretreated August 31, 2018 (n=40) (n=23) (n=17) OR
Slide 10: Monalizumab – Combination with Cetuximab
MONALIZUMAB – COMBINATION WITH CETUXIMAB Overview POTENTIAL NEXT STEPS Accelerated approval strategy if compelling clinical benefit data Ongoing Expansion and/or Partnered in IO pretreated pts Pivotal study Mona + Monalizumab Cetux vs Cetux SCCHN + Cetuximab Mona + Cetux + PD-(L)1 Pivotal study in I
Slide 11: Monalizumab – Commercial Opportunity in SCCHN
MONALIZUMAB – COMMERCIAL OPPORTUNITY IN SCCHN Overview CHANGING COMPETITIVE LANDSCAPE Resectable Unresectable Metastatic 1L 2L 3L IO SOC 35k* 40k* 65k* 25k* 15k* Other SOC Partnered Cis-ineligible Cetuximab + RT Adjuvant CT/RT IO IO +/- CT Proprietary Mono Cis-eligible IO + RT/CT Mona Mona + Cetux +
Slide 12: Proprietary Portfolio: Lumoxiti
PROPRIETARY PORTFOLIO: LUMOXITI FIRST-IN-CLASS TREATMENT FOR HAIRY CELL LEUKEMIA (HCL) 12
Slide 13: Lumoxiti – Strategic First Step to Build a Commercial Portfolio
LUMOXITI – STRATEGIC FIRST STEP TO BUILD A COMMERCIAL PORTFOLIO Overview BRINGING INNOVATIVE TREATMENT TO PATIENTS First-In-Class Treatment for HCL Significant Near-Term Opportunity Label Partnered Filing in the EU expected Current US launch • Approved under FDA priority review in H2 2019 • Adult pa
Slide 14: Lumoxiti – Largest Trial to Date in R/R HCL
LUMOXITI – THE LARGEST TRIAL TO DATE IN PATIENTS WITH R/R HCL Overview CLINICAL PERFORMANCE VS. BENCHMARKS Clinical Performance vs. Benchmarks(1) Moxetumomab PNA(4) Vemurafenib(2) Ibrutinib(2) Rituximab(2) Partnered Pasudotox N=80 N<30 N=28 & 26 N=28 N=24 INV 51.3% 20%-75% 35% & 42%(3) 14% 13% Propr
Slide 15: Lumoxiti – Estimated US Patient Population
LUMOXITI – ESTIMATED US PATIENT POPULATION Overview TREATMENT DETERMINED BY DURATION OF RESPONSE TO PREVIOUS THERAPY Treatment Option Estimated Number of Patients 1st Line Treatment Partnered PNA – Cladribine or Pentostatine ~950 Treatment Option Estimated Number of Patients 2nd Line Proprietary Tre
Slide 16: Lumoxiti – IPH Has Full Commercial Rights to US & EU
LUMOXITI – IPH HAS FULL COMMERCIAL RIGHTS TO US & EU Overview STAGED COLLABORATIVE TRANSITION WITH AZ • In agreement with IPH, AZ will commercialize Lumoxiti in the US up to mid-2020, with IPH beginning co-commercialization activity in mid-2019 Partnered US Rights > $10m sales milestone • IPH is res
Slide 17: Lumoxiti: A Springboard to a Commercial Franchise
LUMOXITI: A SPRINGBOARD TO A COMMERCIAL FRANCHISE Overview Franchise expansion could provide Lumoxiti Leverage access to wide market opportunity now commercial Partnered commercial platform Lumoxiti • EU filing expected 2019, Innate Pharma to take full Lumoxiti commercial rights from 2020 commercial
Slide 18: Proprietary Clinical Pipeline: IPH4102, IPH5401
PROPRIETARY CLINICAL PIPELINE: IPH4102 IPH5401
Slide 19: IPH4102 – First-in-class Anti-KIR3DL2 mAb
IPH4102 – FIRST-IN-CLASS ANTI-KIR3DL2 MAB Overview MECHANISM OF ACTION Partnered Proprietary Financial 19
Slide 20: IPH4102 – Fast to Market Strategy in Sézary Syndrome
IPH4102– FIRST-IN-CLASS ANTI-KIR3DL2 MAB Overview FAST TO MARKET STRATEGY IN SÉZARY SYNDROME • First-in-class cytotoxicity-inducing Sézary syndrome subgroup (35 pts) mAb depleting KIR3DL2+ tumor cells • ORR – 42.9% Partnered • mDoR – 13.8 months • KIR3DL2 is widely expressed on • mPFS – 11.7 months
Slide 21: TELLOMAK Phase II Study
TELLOMAK PHASE II STUDY Overview A PHASE II, OPEN-LABEL, MULTICENTER, MULTI-COHORT STUDY Cohort 1 – Sézary Syndrome IPH4102 ≥ 2 prior systemic therapies that must include mogamulizumab N=60 Single agent Partnered Non-Randomized Cohort 2 & 3 – Mycosis Fungoides ≥ 2 prior systemic therapies including
Slide 22: IPH4102 – Commercial Opportunity
IPH4102 – COMMERCIAL OPPORTUNITY Overview SIGNIFICANT POTENTIAL BEYOND SÉZARY Sézary Advanced CTCL PTCL ATLL 1000 pts* 3200 pts 15000 pts 850 pts Partnered • 15% of all NHL • Highly heterogeneous • Medical need in late lines Proprietary • Differentiated profile • Biomarker driven therapy • Premium p
Slide 23: IPH5401 – First in Class Anti-C5aR mAb
IPH5401 – FIRST IN CLASS ANTI-C5AR MAB Overview NOVEL APPROACH TO IMMUNO-THERAPY Partnered Proprietary C5a stimulates recruitment & activation Inhibition of C5aR signaling shown Financial of suppressor cells & leads to the to increase CD8 T cell infiltration & inhibition of immune effector cells fun
Slide 24: IPH5401 – Unlock the Immune Response with Anti PD-1/PD-L1
IPH5401 – FIRST IN CLASS ANTI-C5AR MAB Overview UNLOCK THE IMMUNE RESPONSE WITH ANTI PD-1/PD-L1 Tumor Incidence * C5aR types expression Partnered NSCLC 290K ~80% Reverse IO resistance HCC 110K ~70% UCC 50K ~70% Proprietary Strategy Enhance IO response CRC 575K 60% Expand into IO TNBC 72K 13-27% refr
Slide 25: IPH5401 – Phase I STELLAR-001 with Durvalumab
IPH5401 – PHASE I STELLAR-001 WITH DURVALUMAB Overview A MULTICENTER, OPEN-LABEL, DOSE-ESCALATION AND DOSE-EXPANSION STUDY Non-exclusive clinical trial collaboration with AstraZeneca: 50% cost sharing Partnered Part 2: Expansion NSCLC – IO Pre-treated Part 1: Dose Escalation Secondary resistance Saf
Slide 26: Preclinical Pipeline: IPH5201 - IPH5301
PRECLINICAL PIPELINE: IPH5201 - IPH5301 (ANTI-CD39) AND (ANTI-CD73, PROPRIETARY) MABS 26
Slide 27: IPH5201 (Anti-CD39) and IPH5301 (Anti-CD73)
IPH5201 (ANTI-CD39, FIRST-IN-CLASS) AND IPH5301 (ANTI-CD73) TARGETING IMMUNOSUPPRESSIVE TUMOR MICROENVIRONMENT • CD39 and CD73 are enzymes expressed on different cells in the TME > Promote immuno-suppression by degrading pro-inflammatory ATP into immunosuppressive adenosine • IPH5201 and IPH5301 blo
Slide 28: Expanded Research Collaboration with AZ
EXPANDED RESEARCH COLLABORATION WITH AZ Overview VALIDATES IPH’S LEADING IMMUNO-ONCOLOGY PLATFORM IPH5201 (anti-CD39) Research Collaborations – Key Terms Partnered • Anti-CD39 antibody Overview • IPH to grant AZ the option to an • Blocks the enzyme activity of both soluble Rights Granted and membran
Slide 29: Financial Data and News Flow
FINANCIAL DATA AND NEWS FLOW
Slide 30: Financial Highlights: Review of AstraZeneca Proceeds & Payments
FINANCIAL HIGHLIGHTS Overview REVIEW OF ASTRAZENECA PROCEEDS & PAYMENTS 2018: Dec 31 2019: March 31 Partnered Innate received ~€103m ($118m) consisting of: Innate received ~€108.7m ($124m) consisting of: • €62.6m ($72m) from the equity investment • €87.6m ($100m) from the monalizumab payment* • €22.
Slide 31: Financial Highlights First Quarter 2019
FINANCIAL HIGHLIGHTS FIRST QUARTER 2019 Overview Cash, cash equivalents and Revenue/other income: Partnered financial assets* • € 237.1m as of March 31, • Licensing and collaborations: 2019 €13.9m • (€202.7m as of December • (€8.7m for 1Q2018) 31, 2018**) • Spreading of initial Proprietary payments
Slide 32: Financial Highlights 2018
FINANCIAL HIGHLIGHTS 2018 Overview In thousands of euros, except for data per share 31-Dec-18 31-Dec- 2017 * Δ Revenue and other income 93,952 36,221 57,731 Research and development -69,555 -58,962 -10,593 General and administrative -18,142 -17,015 -1,127 Partnered Net result from Lumoxiti agreement
Slide 33: Key Pipeline Events in the Next Months
INNATE PHARMA – KEY PIPELINE EVENTS IN THE NEXT 18 MONTHS Overview FOCUS ON CLINICAL AND COMMERCIAL EXECUTION H1-2019 H1-2019 H2-2019 2020 Partnered US commercial organization build up Lumoxiti commercial ops. in US Lumoxiti launch in EU • Transition phase with AZ IPH4102 - TELLOMAK phase II study s
Slide 34: Investor Relations
INVESTOR RELATIONS investors@innate-pharma.com US Danielle Spangler Tel : +1 917 499 6240 EUROPE Markus Metzger Tel : +33 (0)4 84 90 31 85 Jérôme Marino Tel : +33 (0)4 84 90 31 91 Page 34